Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 12/11/25 | Azura Ophthalmics | AZR-MD-001 for Dry Eye (Ophthalmology) | Subscribers Only | Subscribers Only | Subscribers Only |
| 12/9/25 | MaaT Pharma | Xervyteg for Graft vs. Host Disease (GVHD) - Treatment | Subscribers Only | Subscribers Only | Subscribers Only |
| 12/8/25 | Ascletis (1672) | ASC30 for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 12/8/25 | Galapagos (GLPG) | GLPG5101 for Mantle Cell Lymphoma - NHL | Subscribers Only | Subscribers Only | Subscribers Only |
| 12/8/25 | Geron (GERN) | Rytelo for Myelodysplastic Syndrome (MDS) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/30/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Patient Enrollment Completed |
| 01/01/2026 - 06/30/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |